Monday, August 10, 2020 4:06:51 PM
4:02 pm ET August 10, 2020 (Globe Newswire) Print
- Initiation of CLS-AX Phase 1/2a Clinical Trial in Wet AMD Targeted by Year-End 2020 -
Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for CLS-AX (axitinib injectable suspension), enabling initiation of a Phase 1/2a clinical trial of CLS-AX in neovascular age-related macular degeneration (wet AMD) patients by the end of 2020.
"The FDA's acceptance of our IND submission for CLS-AX is a significant achievement for Clearside and demonstrates our ability to successful move another internally-developed program into the clinic," said George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer. "As a tyrosine kinase inhibitor (TKI), axitinib has demonstrated pan-VEGF inhibition in independent studies and may have the potential to be more efficacious than current, more narrowly focused VEGF inhibition approaches. In our internal preclinical studies, CLS-AX delivered through suprachoroidal injection was well tolerated and showed durability over several months, providing Clearside the opportunity to potentially reduce treatment burden and address a primary need for wet AMD patients. We look forward to initiating clinical work by the end of 2020."
The Phase 1/2a clinical trial in wet AMD patients is expected to be an open-label, dose-escalation study to assess the safety and tolerability of single doses of CLS-AX administered through suprachoroidal injection following two or more prior treatments with an intravitreal anti-VEGF agent.
Recent CLSD News
- Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024 • GlobeNewswire Inc. • 04/30/2024 11:05:00 AM
- Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors • GlobeNewswire Inc. • 04/16/2024 11:05:00 AM
- Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/02/2024 11:05:00 AM
- Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer • GlobeNewswire Inc. • 03/18/2024 11:05:00 AM
- Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/12/2024 08:05:00 PM
- Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024 • GlobeNewswire Inc. • 02/29/2024 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 10:05:05 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/08/2024 09:52:44 PM
- Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering • GlobeNewswire Inc. • 02/07/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 09:01:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 11:25:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/19/2024 08:04:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:10:07 PM
- Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD • GlobeNewswire Inc. • 12/14/2023 12:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:30:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:10:13 PM
- Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/13/2023 09:05:00 PM
- Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference • GlobeNewswire Inc. • 11/08/2023 12:05:00 PM
- Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting • GlobeNewswire Inc. • 11/07/2023 09:20:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 04:01:10 PM
- BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector® • GlobeNewswire Inc. • 11/03/2023 04:00:00 PM
- Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting • GlobeNewswire Inc. • 11/02/2023 11:05:00 AM
- Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD • GlobeNewswire Inc. • 11/01/2023 11:05:00 AM
- Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023 • GlobeNewswire Inc. • 10/31/2023 11:05:00 AM
- Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting • GlobeNewswire Inc. • 10/16/2023 11:05:00 AM
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM